Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine (PRME) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $134000.0 in Q1 2024.

• For the quarter ending Q1 2024, Non-Current Deferred Tax Liability rose 74.03% year-over-year to $134000.0; the trailing twelve-month figure through Mar 2024 stood at $134000.0 (up 74.03% YoY), and the FY2022 full-year result was $8.7 million, up 46.57% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2024 stood at $134000.0, up from $108000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $8.7 million in Q4 2022 and bottomed at $77000.0 in Q1 2023.
• The 4-year median for Non-Current Deferred Tax Liability is $307500.0 (2022), against an average of $2.6 million.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability soared 46.57%; it then surged 74.03% in 2024.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $6.0 million in 2021, then soared by 46.57% to $8.7 million in 2022, then tumbled by 98.77% to $108000.0 in 2023, then increased by 24.07% to $134000.0 in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $134000.0 (Q1 2024), $108000.0 (Q2 2023), and $77000.0 (Q1 2023), per Business Quant data.

Peer Comparison